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Abstract: Background: Implementing a successful antimicrobial stewardship program (ASP)
is difficult for non-academic community (NAC) hospitals due to insufficient infrastructure.
Aim: We evaluated the impact of an infectious disease specialist (IDS) on implementing an
ASP in a resource-limited setting in Korea. Methods: A retrospective study was performed at
a NAC hospital between June 2015 and August 2018. An IDS has led an ASP at the hospital
since June 2017. We used an interrupted time series analysis to evaluate longitudinal effects of
the IDS-led ASP on the amount of antibiotic use and incidence of multidrug-resistant organism
(MDRO) acquisition. Findings: Total antibiotic use changed from 698.82 ± 74.41 to 602.09 ± 69.94
defined daily dose/1000 patient-days (PDs) after intervention. An immediate reduction in the
use of carbapenems, glycopeptides, penicillins, and other antibiotics followed the IDS-led ASP.
The 3rd/4th generation cephalosporins and carbapenems prescription rates decreased in slope after
the intervention. Incidence of MDRO acquisition changed from 1.38, 0.78, and 0.21/1000 PDs
to 1.06, 0.15, and 0.32/1000 PDs in methicillin-resistant Staphylococcus aureus, multidrug-resistant
Acinetobacter baumannii, and multidrug-resistant Pseudomonas aeruginosa, respectively. The incidence of
methicillin-resistant Staphylococcus aureus and multidrug-resistant Acinetobacter baumannii acquisition
immediately decreased following intervention. Conclusion: An IDS can implement a successful ASP
by reducing antibiotic consumption and MDRO acquisition at resource-limited NAC hospitals.
Keywords: anti-bacterial agents; antimicrobial stewardship program; infectious disease specialist;
antimicrobial resistance; community hospital; Korea
1. Introduction
Use of antimicrobial agents has reduced mortality in infectious diseases. However, excessive antibiotic
use has caused development of antimicrobial resistance (AMR) in bacteria [1,2]. Infection with an
antimicrobial resistant organism has become a major public health concern due to its difficulty to treat,
resulting in an increase in hospital stays, cost, and mortality [3]. While antimicrobial resistant organisms
have been increasing rapidly, only a few new drugs for combating these pathogens have been developed [4].
An antimicrobial stewardship program (ASP) is one of the most important strategies for preventing
AMR [5,6]. In addition, an ASP can improve clinical outcomes in patients while reducing adverse
drug reactions [7]. With the proven advantages of ASPs, the necessity for such programs has been
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realized in most hospitals, regardless of bed size or teaching status. The importance of the role of an
infectious disease specialist (IDS) in implementing a successful ASP has been proven through previous
studies [8–10]. However, most of these studies evaluated the role of an IDS and the effects of an ASP in
large, academic hospitals.
On the other hand, only a few studies have reported successful implementation of ASPs in
non-academic community (NAC) hospitals [11,12]. NAC hospitals would need modified strategies
to implement ASPs because they have fewer resources to allocate to them than do large or teaching
hospitals. In Korea, while most NAC hospitals have been challenged to implement ASPs, most of them
do not have facility leadership support available. Most IDSs have worked in large, academic hospitals,
and they are rarely hired by NAC hospitals.
Since the Middle East respiratory syndrome-coronavirus outbreak in 2015, the Korean government
has been encouraging hospitals to employ infection control doctors by policy. Consequently, the
Korean National Health Insurance Service now reimburses infection control costs on the condition
that doctors and nurses be allocated for infection control in hospitals with more than 300 beds [13].
Accordingly, there has been a recent increase in the number of IDSs working as infection control doctors
in NAC hospitals. These IDSs are expected to play a major role in ASPs; however, this has not yet been
fully evaluated.
We hypothesized that having an IDS could be a potential solution for implementing a successful
ASP in a resource-limited setting. The aim of this study was, therefore, to evaluate the impact of an
IDS-led ASP through the changes in the amount of antibiotic use and the rate of multidrug-resistant
organism (MDRO) acquisition at a resource-limited NAC hospital in Korea.
2. Materials and Methods
2.1. Study Population and Data Collection
We conducted a retrospective study at Kimpo Woori Hospital, a NAC hospital with 402
beds in Korea. All patients admitted to the hospital between June 2015 and August 2018
were eligible to participate. Of these, we included 578 patients who had positive cultures
for methicillin-resistant Staphylococcus aureus (MRSA), multidrug-resistant Acinetobacter baumannii
(MDRAB), and multidrug-resistant Pseudomonas aeruginosa (MDRPA) from any type of specimen
received at least 48 h after admission. Multidrug-resistance was defined as resistance to at least one
antibiotic between carbapenems, aminoglycosides, and fluoroquinolones.
Data of all patients were included for statistical analysis only once for each organism. We collected
the data on clinical characteristics from electronic medical records. Patients’ underlying comorbidities
were defined using the International Classification of Diseases, 10th revision. Microorganisms were
identified using a VITEK-2 automated bacterial identification system (bioMerieux, Marcy-I’Etoile,
France). Antimicrobial susceptibility testing was interpreted using the Clinical and Laboratory
Standards Institute guidelines [14]. This study was approved by the Institutional Review Board of
Yonsei University Health System Clinical Trial Center (approval number 4-2019-0519), and the protocol
adhered to the tenets of the Declaration of Helsinki. Since the study was retrospective in nature and
the study participants were anonymized, the Institutional Review Board waived the requirement for
written consent from the patients.
2.2. Amount of Antibiotic Consumption
We collected the data for monthly antibiotic prescriptions to evaluate the trend in the amount
of antibiotic use. This study included only parenteral antibiotics and excluded oral or topical agents.
Classification and defined daily doses (DDDs) of antibiotics were determined according to the World
Health Organization Anatomical Therapeutic Chemical Classification [15]. We grouped antibiotics as
follows: aminoglycosides, 1st/2nd and 3rd/4th generation cephalosporins, carbapenems, glycopeptides,
fluoroquinolones, penicillins, and other antibiotics, including linezolid, colistin, and tigecycline.
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2.3. The Intervention
In March 2015, the hospital implemented an initial ASP led by an internal medicine physician
without infectious disease training. Associated polices were defined, and bylaws were introduced
throughout the hospital. The policies mainly aimed to limit inappropriate use of prophylactic antibiotics
for surgery, which restricted prescription of 3rd generation cephalosporins and aminoglycoside for
surgery. Additionally, computerized prescription monitors produced pop-up alarms when physicians
continued to prescribe antibiotics designated as restricted, such as linezolid, colistin, tigecycline,
glycopeptides, and carbapenems, for more than 3 days. The pop-up alarm system did not restrict or
monitor prescription of antibiotics designated as restricted.
The hospital hired an IDS for the first time in March 2017. Three months later, the IDS began
to lead the ASP. The ASP was enforced to reduce MDROs and the amount of antibiotic use in the
hospital beginning in June 2017. The IDS intended to reduce the use of inappropriate antibiotic
combinations, such as overlap in antimicrobial coverage, as well as inappropriate use of prophylactic
antibiotics for surgery. Furthermore, he endeavored to increase the appropriate use of carbapenems,
glycopeptides, anti-pseudomonal cephalosporins (ceftazidime and cefepime), and other antibiotics
(linezolid, colistin, and tigecycline). All physicians were required to consult the IDS for prescription of
antibiotics designated as restricted. The IDS assessed the appropriateness of using those antibiotics and
recommended the proper dosage and interval and optimal duration of treatment through consultations
with the physicians. He also checked the results of culture studies at 5 to 7 days after the approval of
antibiotic use and made the decision whether to continue a prescription.
2.4. Statistical Analysis
The change in pattern of antibiotic consumption and MDRO acquisition in accordance with the
IDS-led ASP between June 2015 and August 2018 was analyzed using an interrupted time series [16].
After implementation of the intervention in June 2017, we set a transition period of three months to
allow the intervention process to stabilize. This study divided the time series into two segments, pre-
and post-intervention. We used segmented regression analysis to assess the longitudinal effect of the
IDS-led ASP. Parameters used in segmented regression analysis were defined as follows. The level
was considered the value of a measure at the beginning of a time segment. The trend was considered
the rate of change for the measure during the given time interval. The level change after intervention
was considered the average value of change after intervention, reflecting the immediate effect of the
intervention. The trend change after intervention was considered to be the change in slope during
the period after intervention, constituting a gradual change during the segment. The Durbin–Watson
statistic was used to test for the presence of autocorrelation, and we verified no serious autocorrelation.
We compared the clinical characteristics of each patient with MDRO acquisition for one year before
and after the intervention using either the independent t-test or the Chi-square test.
Statistical analyses were performed using SAS version 9.4 (SAS Institute, Inc., Cary, NC, USA.) or
R software version 3. Statistical significance was considered as p < 0.05.
3. Results
3.1. Clinical Characteristics of Patients
Between June 2016 and August 2018, the most prevalent organism reported in clinical
specimens was MRSA (n = 362), followed by MDRAB (n = 139) and MDRPA (n = 77) (Table 1).
Clinical characteristics of patients with hospital-acquired MRSA and MDRPA acquisition did not
differ statistically before and after the intervention. Among the patients with MDRAB acquisition,
the proportion of those having solid cancer or cardiovascular disease were higher in the post-intervention
period than in pre-intervention.
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Table 1. Clinical characteristics of patients with hospital-acquired multidrug-resistant organisms between June 2016 and August 2018.
Variables
Methicillin-Resistant Staphylococcus
aureus
Multidrug-Resistant Pseudomonas
aeruginosa
Multidrug-Resistant Acinetobacter
baumannii
One Year
before
Intervention
(n = 217)
One Year
after
Intervention
(n = 145)
p-value
One Year
before
Intervention
(n = 33)
One Year
after
Intervention
(n = 44)
p-value
One Year
before
Intervention
(n = 118)
One Year
after
Intervention
(n = 21)
p-value
Age, years (IQR) 77 ± 13.6 75 ± 15.98 0.184 77 ± 13.33 73 ± 15.13 0.26 76 ± 14.26 77 ± 11.34 0.73
Male, n (%) 129 (59.5) 97 (66.9) 0.152 16 (48.5) 25 (56.8) 0.468 38 (32.2) 7 (33.3) 0.919
Antibiotic use in the past
30 days, n (%) 166 (76.5) 95 (65.5) 0.065 27 (81.8) 40 (90.9) 0.291 107 (90.7) 18 (85.7) 0.536
Comorbidities, n (%)
Diabetes 73 (33.6) 41 (28.3) 0.282 13 (39.4) 10 (22.7) 0.114 37 (31.4) 8 (38.1) 0.543
Solid cancer 34 (15.7) 28 (19.3) 0.278 6 (18.2) 7 (15.9) 0.792 21 (17.8) 8 (38.1) 0.044
Hematologic malignancy 1 (0.5) 2 (1.4) 0.567 1 (3.0) 1 (2.3) >0.999 1 (0.9) 0 (0.0) >0.999
Solid organ transplantation 0 (0.0) 0 (0.0) - 0 (0.0) 0 (0.0) - 0 (0.0) 0 (0.0) -
Hematologic stem cell
transplantation 0 (0.0) 1 (0.7) 0.401 0 (0.0) 1 (2.3) >0.999 0 (0.0) 0 (0.0) -
Rheumatologic disease 4 (1.8) 2 (1.4) >0.999 0 (0.0) 0 (0.0) - 0 (0.0) 0 (0.0) -
Cardiovascular disease 139 (64.1) 96 (66.2) 0.674 20 (60.6) 28 (63.6) 0.786 73 (61.9) 18 (85.7) 0.034
Chronic obstructive
pulmonary disease 33 (15.2) 26 (17.9) 0.492 2 (6.1) 8 (18.2) 0.174 18 (15.3) 5 (23.8) 0.344
Renal Disease 60 (27.7) 42 (29.0) 0.785 6 (18.2) 7 (15.9) 0.792 30 (25.4) 6 (28.6) 0.762
Liver disease 45 (20.7) 32 (22.1) 0.762 4 (12.1) 9 (20.5) 0.334 18 (15.3) 3 (14.3) >0.999
HIV infection 0 (0.0) 0 (0.0) - 0 (0.0) 0 (0.0) - 0 (0.0) 0 (0.0) -
Hemodialysis 16 (7.4) 10 (6.9) 0.863 2 (6.1) 6 (13.6) 0.454 8 (6.8) 2 (9.5) 0.648
Neutropenia 0 (0.0) 1 (0.7) 0.401 0 (0.0) 0 (0.0) - 0 (0.0) 0 (0.0) -
Steroid therapy 16 (7.4) 10 (6.9) >0.999 2 (6.1) 2 (4.6) 0.347 14 (11.9) 2 (9.5) >0.999
Immunosuppressive
therapy 0 (0.0) 0 (0.0) - 0 (0.0) 0 (0.0) - 0 (0.0) 0 (0.0) -
Chemotherapy 0 (0.0) 3 (2.1) 0.064 0 (0.0) 1 (2.3) >0.999 0 (0.0) 0 (0.0) -
Radiotherapy 0 (0.0) 0 (0.0) - 0 (0.0) 0 (0.0) - 0 (0.0) 0 (0.0) -
Note: IQR, interquartile range; HIV, human immunodeficiency virus.
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3.2. Amount of Antibiotic Consumption
Total antibiotic use changed from 698.82 ± 74.41 DDD/1000 patient-days (PDs) to 602.09 ± 69.94
DDD/1000 PDs during study period (Table S1). Following the intervention, amount of most antibiotic
use decreased, except 1st/2nd generation cephalosporin, which increased from 93.76 ± 10.13 DDD/1000
PDs to 96.2 ± 14.15 DDD/1000 PDs. We demonstrated antibiotic consumption patterns between June
2015 and August 2018 in Figure 1.
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According to segmented regression analysis, there was a decreasing trend in the amount of
aminoglycoside and quinolone consumption before the intervention (p < 0.001 for each antibiotic)
(Table 2). Following the intervention, decreases in both level and trend of the total amount of
antibiotics consumed were not statistically significant. However, the intervention had a prominent
effect on the use of antibiotics designated as restricted. Just after the transition period, among the
antibiotics designated as restricted, there was an immediate reduction in the use of carbapenems
(coefficient −16.108, p = 0.033), glycopeptides (coefficient −12.287, p = 0.012), and other antibiotics
(coefficient −16.092, p = 0.043). Although significant immediate change was not observed in the
amount of 3rd/4th generation cephalosporins use, including that of ceftazidime/cefepime, there was a
significant decreasing trend following the intervention as compared with that during pre-intervention
(coefficient −8.459, p = 0.004). In addition to the immediate response, use of carbapenems showed
a significant decreasing trend after the intervention (coefficient −2.029, p = 0.027). Penicillins were
not subject to restriction, but their use decreased immediately after the intervention. Following an
immediate reduction after the transition period, there was no significant change in the trend of use of
glycopeptides, penicillins, and other antibiotics.
Table 2. Segmented regression model predicting monthly daily defined dose per 1000 patient-days in
the hospital.
Antibiotics Coefficient Standard Error p-Value
Aminoglycosides
Baseline level 22.0256 0.9929
Baseline trend −0.3305 0.0695 <0.001
Level change after intervention 0.8123 1.7243 0.641
Trend change after intervention −0.2064 0.2089 0.331
1st/2nd generation cephalosporins
Baseline level 101.9253 4.6246
Baseline trend −0.6535 0.3237 0.052
Level change after intervention 1.9191 8.0315 0.813
Trend change after intervention 1.891 0.9732 0.061
3rd/4th generation cephalosporins
Baseline level 177.211 13.0193
Baseline trend 1.7935 0.9112 0.058
Level change after intervention 11.108 22.6103 0.627
Trend change after intervention −8.4598 2.7399 0.004
Ceftazidime/cefepime
Baseline level 66.3764 8.7921
Baseline trend 0.5003 0.6153 0.422
Level change after intervention −7.0211 15.269 0.649
Trend change after intervention −5.663 1.8503 0.004
Carbapenems
Baseline level 39.3779 4.1486
Baseline trend 0.4704 0.2903 0.115
Level change after intervention −16.1077 7.2047 0.033
Trend change after intervention −2.0287 0.8731 0.027
Glycopeptides
Baseline level 35.0324 2.6622
Baseline trend 0.1151 0.1863 0.541
Level change after intervention −12.2869 4.6233 0.012
Trend change after intervention −0.885 0.5602 0.124
Penicillins
Baseline level 140.8157 12.7416
Baseline trend 0.5614 0.8917 0.533
Level change after intervention −46.7517 22.128 0.043
Trend change after intervention 4.2492 2.6814 0.123
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Table 2. Cont.
Antibiotics Coefficient Standard Error p-Value
Fluoroquinolones
Baseline level 115.0862 6.0155
Baseline trend −1.8856 0.421 <0.001
Level change after intervention 4.1865 10.447 0.691
Trend change after intervention 1.0813 1.2659 0.399
Other antibiotics
Baseline level 64.8456 4.395
Baseline trend 0.1295 0.3076 0.677
Level change after intervention −16.0924 7.6328 0.043
Trend change after intervention 0.185 0.9249 0.843
Total antibiotics
Baseline level 696.3197 31.5014
Baseline trend 0.2003 2.2046 0.928
Level change after intervention −73.2129 54.7076 0.19
Trend change after intervention −4.1733 6.6293 0.536
3.3. Incidence of MDRO Acquisition
From June 2015 to May 2017 (the period before the intervention), the incidence of MDRO
acquisition was 1.381, 0.213, and 0.777/1000 PDs in MRSA, MDRAB, and MDRPA, respectively
(Table S2). The incidence of MRSA and MDRAB acquisition decreased following the intervention
(1.06/1000 PDs in MRSA and 0.15/1000 PDs in MDRAB). However, during the same period, there was
an increase in the incidence of MDRPA acquisition (0.32/1000 PDs). The incidence of MDRO acquisition
in patients admitted to the hospital during the study period is presented in Figure 2.
In segmented regression analysis, a significant increasing trend was observed in the incidence of
MRSA acquisition before the intervention (coefficient 0.03, p < 0.001) (Table 3). Immediately following
the transition period, the estimated incidence of MRSA acquisition decreased (coefficient −0.71,
p < 0.001). There was no significant changing trend in the incidence of MDRAB and MDRPA before the
intervention. The incidence of MDRAB acquisition dropped after the transition period (coefficient−0.62,
p = 0.014); however, MDRPA acquisition increased (coefficient 0.21, p = 0.035). There was no significant
trend change in the incidence of acquisition of each MDRO after the intervention.
Table 3. The incidence of multidrug-resistant organisms acquisition among patients in the hospital
over time using segmented regression analysis.
Multidrug-Resistant Organisms Coefficient Standard Error p-Value
Methicillin-resistant Staphylococcus aureus
Baseline level 1.05 0.10
Baseline trend 0.03 0.01 0.001
Level change after intervention −0.71 0.18 <0.001
Trend change after intervention −0.02 0.02 0.439
Multidrug-resistant Pseudomonas aeruginosa
Baseline level 0.19 0.06
Baseline trend 0.002 0.004 0.628
Level change after intervention 0.21 0.10 0.035
Trend change after intervention −0.02 0.01 0.082
Multidrug-resistant Acinetobacter baumannii
Baseline level 0.85 0.13
Baseline trend −0.01 0.01 0.569
Level change after intervention −0.62 0.24 0.014
Trend change after intervention 0.02 0.03 0.588
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4. Discussion
Here, we have demonstrated the impact of an IDS on the implementation of an ASP at a
resource-limited NAC hospital in Korea. The intervention had an immediate effect on the reduction in
antibiotics designated as restricted. Moreover, there was a continuous decreasing trend in the use of
some antibiotics after the intervention. In addition, along with the decreased amount of antibiotic use,
the incidence of MRSA and MDRAB acquisition decreased immediately following the IDS-led ASP
without a significant trend change after the immediate effect.
Data on antibiotic use in NAC hospitals are limited in Korea. We previously reported on the
amount of antibiotic use in a large, university-affiliated hospital [17]. Compared with the rate at
this major teaching hospital, our current study demonstrated a similar usage rate of antibiotics in
the NAC hospital. Other studies have also reported that hospital size is not important in predicting
the amount of antibiotic use [18,19]. Given these findings, regardless of bed size or medical school
affiliation, all hospitals should be required to implement ASPs. However, the majority of Korean NAC
hospitals still do not have these programs because of insufficient human, financial, and information
technology resources as compared with large, academic medical centers. For example, a pharmacist
should be involved in an ASP; however, most Korean NAC hospitals do not have a staff member with
drug expertise as one of the core elements for a successful hospital ASP [20]. In addition, although
NAC hospitals do implement ASPs, there are barriers to the success of these programs. First, a large
proportion of patients in NAC hospitals come from long-term care facilities; therefore, they are likely
to suffer from recurrent aspiration pneumonia or severe decubitus ulcers, which result in an increased
chance of antibiotic use [21]. Second, compared to in large academic hospitals, reducing antibiotic use,
especially well-reimbursed drugs, may not be financially beneficial in NAC hospitals [12]. Therefore,
ASPs may not be receiving sufficient support from hospital leadership.
Having an IDS could be a potential solution for implementation of a successful ASP at
disadvantaged NAC hospitals. IDS consultation can reduce antibiotic use through the discontinuation
of inappropriate antibiotics and an increase in appropriate antibiotic use by changing to narrow
spectrum antibiotics [22]. In addition, involvement of an IDS in clinical practice has been associated
with improved patient outcomes [23]. The skill set of an IDS engenders trust in other physicians,
making them receptive to IDS suggestions for appropriate antibiotic use. In this study, the use of
1st/2nd generation cephalosporins tended to increase after the intervention (coefficient 1.891, p = 0.061),
although these results were not statistically significant. This may have been caused by the change
made by the IDS from empirical antibiotics that had been improperly used to appropriate antibiotics.
Similar studies have been conducted in small NAC hospitals with fewer than 200 beds. In these
studies, ASPs have also been proven to reduce antibiotic use, lower medical costs, and improve
antibiotic susceptibilities to specific pathogens [24–27]. Even though IDSs spent much less time on
the ASP than that in our study, they demonstrated successful results after implementation of ASP.
However, key differences exist in our study compared to these other studies. First, most of the hospitals
had pharmacists who were dedicated to the ASP and facilitated the intervention, but we did not
have a pharmacist as a member of the ASP team because of the lack of available pharmacists in
Korean NAC hospitals. Second, it takes less time to develop and maintain an ASP in smaller hospitals.
Stenehjem et al. [12] reported that the average time spent on the ASP is 5–10 hours per week in hospitals
with 70–150 beds. In contrast, in our study the IDS was required to work full time in the hospital,
which has 402 beds, and dedicate the most time to ASP activities. In addition, a low volume of patients
and staff members means that once IDS-led ASPs are well established in smaller NAC hospitals, we
can expect more rapid effects and better compliance than in larger NAC hospitals. Therefore, we think
that this study, conducted in moderate-sized, resource-limited NAC hospital, is worthwhile.
There are multiple factors associated with the development of AMR. Several studies have shown
strong evidence suggesting that an effective ASP can reduce the prevalence of AMR, as well as
antibiotic use [10,28–30]. Our study also shows that an IDS-led ASP can effect a reduction in AMR.
We evaluated the incidence of MRSA, MDRAB, and MDRPA acquisition as indicators of AMR. In Korea,
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these pathogens are not only isolated frequently in clinical specimens, but also cause relevant infections
in clinical practice. About 66% of Staphylococcus aureus has methicillin resistance, and the carbapenem
resistance of Acinetobacter baumannii and Pseudomonas aeruginosa are 85% and 35%, respectively [31].
However, we were unable to evaluate the incidence of carbapenem-resistant Enterobacteriaceae (CRE),
because there were few cases of hospital-acquired CRE in the facility studied. Most CRE cases were
confirmed in specimens collected prior to 48 h after admission.
A limitation of this study is that an infection control program could be a confounding factor
for a decrease in the incidence of MDRO acquisition. However, this factor is unlikely to affect our
results. The IDS spent some time meeting with the infection control team—which had been in existence
and was doing well in the hospital before he arrived—to implement infection control activities.
There was no significant change in the methods of the infection control program. For example, the main
strategy for hand hygiene was education, monitoring, and feedback during the study period, and the
performance rate was maintained at 81.3% to 88.4%. Another limitation was the immediate increase in
the incidence of MDRPA acquisition despite a significant decrease in carbapenem use. A previous
study showed that reduced carbapenem use was associated with a decrease in carbapenem resistance
in Pseudomonas aeruginosa [28], although we did not observe the same results. However, although
there was no statistical significance, incidence of MDRPA acquisition had decreased in slope following
the intervention.
5. Conclusions
ASP is an effective strategy to prevent or slow the development of MDROs. However, it is difficult
for NAC hospitals to implement a successful ASP due to the lack of multidisciplinary resources. We
have shown that an IDS could be a potential solution for successful implementation of an ASP in
resource-limited settings. Our findings should, however, be verified in different settings, such as
smaller institutions, thus facilitating the need for further study.
Supplementary Materials: http://www.mdpi.com/2077-0383/8/9/1293/s1. Table S1: Amount of antibiotic
consumption before and after the intervention. Table S2: The incidence of multidrug-resistant organisms
before and after intervention.
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